Non-resident Indians are buying health insurance in India at a sharply rising rate, The Economic Times reported, and the trend is pulling more of them home for treatment. The paper, citing figures from Policy Bazaar, an Indian insurance marketplace, said the number of NRIs taking out health cover in India had grown 150 per cent year on year. That matters less as an insurance statistic than as a change in how the diaspora pays for care. A cash decision once made in a crisis is becoming a planned, insured one made in advance. That is the kind of shift that turns occasional medical travel into a habit.
The draw underneath the insurance is cost, and the gaps are wide. Major procedures in India run 60 to 90 per cent below prices in the United States and the United Kingdom, the paper reported. A heart bypass priced at US$70,000 to US$150,000 in the West is performed in India for about US$5,000 to US$8,000. A knee replacement costs US$4,000 to US$6,000 against US$30,000 to US$50,000 abroad, and a liver transplant US$25,000 to US$35,000 against figures that can reach US$500,000. Typical claims by NRIs fall between US$2,000 and US$15,000, Policy Bazaar said, and rarely pass US$40,000 even for complex surgery.
Insurance is the new part
Cost arbitrage is an old story; the insurance is what has changed. Health premiums in India start as low as US$120 to US$300 a year, the paper reported, against more than US$8,000 an individual in the United States and around US$4,000 to US$5,000 in the Gulf. That gap is what makes an Indian policy worth holding from abroad. Much of the buying is done by NRIs insuring elderly parents who live in India rather than themselves, the paper said. Policy Bazaar reported a 60 per cent rise in searches for health insurance in India aimed at NRIs, and a 45 per cent rise in searches for treatment of overseas citizens there.
Those search figures are demand signals rather than arrivals, and they come from a company that sells the policies. A 150 per cent rise in a broker’s own book of non-resident policies shows the broker growing. It is consistent with a wider trend, but it is not an independent count of patients treated. The paper presented the numbers as evidence of momentum, and read that way they point in a clear direction without settling the size of the flow.
The map is shifting inland
The distribution of claims complicates the usual picture of Indian medical tourism as a business of a few metros. Tier-3 cities now account for 46 per cent of non-resident claims, the paper reported, ahead of Tier-2 at 33 per cent and Tier-1 at 21 per cent. The reason is that policies bought for elderly parents are used where those parents live. South India carries much of the demand, with Hyderabad, Chennai, Mumbai, Bengaluru and Kolkata leading among the larger cities. Kerala’s smaller centres feature strongly, the paper said, with Ernakulam and Thiruvananthapuram among the Tier-2 cities and Thrissur, Kollam and Kozhikode among the Tier-3. Infectious diseases were the most common reason for a claim at 18 per cent, followed by respiratory conditions, cancer and heart disease.
Cheap medicine reinforces the arithmetic. India’s generics cut costs far below Western prices, the paper reported. Insulin that runs US$100 to US$300 in the United States is available for a few dollars, and the cancer drug imatinib, which can exceed US$10,000 a month, sells in India for US$100 to US$500. Insurers are adding on-the-ground help for non-resident families, the paper said, covering travel logistics, admission and post-treatment care. That is the practical support that decides whether a distant relative’s operation goes smoothly. Culturally familiar care, English-speaking staff and virtually no waiting lists round out the appeal, with private chains such as Apollo and Tata Memorial handling the complex cases.
A diaspora-led market
There is a standing risk worth naming in a trend built this way, and it is concentration. The demand here rests on one diaspora making one kind of decision, insuring parents at home. A market that leans on a single source group is exposed to that group’s circumstances in a way a broader base is not. The cost advantage that drives it is durable, and the insurance layer makes the flow steadier than cash-paid treatment ever was. Even so, the trend is still a diaspora story before it is a general one.
India’s government is counting on demand of this kind to lift the wider sector. The Economic Times tied the trend to the Heal in India initiative and to a projection that medical tourism will reach US$13 billion by 2026. That figure has framed several accounts of the country’s push toward a 13-billion-dollar market and its longer forecast toward 16.2 billion by 2030. Those are projections. The insured policies and the claims paid on them are the nearer, checkable measure of whether the demand is real.
What to watch
The tests are countable. Whether the share of non-resident claims in Tier-3 cities holds near 46 per cent, or slips back toward the metros, will show whether India’s inland hospitals are keeping the patients the insurance is sending them. Whether independent arrival and revenue figures, rather than a broker’s policy count, begin to match the 150 per cent growth Policy Bazaar reported will show how much of the trend is patients and how much is paperwork. Whether the Heal in India programme and the US$13 billion projection are met by 2026 will show whether the diaspora demand scaled into the market the government has promised.
